Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $158.1 million.

  • Iovance Biotherapeutics' Cash & Equivalents fell 3.69% to $158.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.1 million, marking a year-over-year decrease of 3.69%. This contributed to the annual value of $115.7 million for FY2024, which is 0.70% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Cash & Equivalents of $158.1 million as of Q3 2025, which was up 19.35% from $132.5 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Cash & Equivalents registered a high of $543.5 million during Q1 2023, and its lowest value of $114.9 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Equivalents was $164.2 million (2024), whereas its average is $205.6 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Cash & Equivalents plummeted by 75.31% in 2024 and then increased by 27.95% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Cash & Equivalents stood at $114.9 million in 2023, then climbed by 0.70% to $115.7 million in 2024, then dropped by 3.69% to $158.1 million in 2025.
  • Its Cash & Equivalents stands at $158.1 million for Q3 2025, versus $132.5 million for Q2 2025 and $171.7 million for Q1 2025.